Considering Alternatives to Psychedelic Drug Prohibition

Format:

Book

Author/Creator:

Kilmer, Beau

Contributor:

Palmer, Keytin

Priest, Michelle

Ramchand, Rajeev

Rogers, Rhianna C.

Senator, Ben

Language:

English

Place of Publication:

RAND Corporation 2024

Summary:

Psychedelic substances, such as psilocybin mushrooms and LSD, have long been touted as holding promise for treating various mental health conditions, and the past decade has seen another round of enthusiasm for this hope. Although the clinical research and associated media reports on these substances continue to grow, what receives less attention is the changing policy landscape for some psychedelics in the United States. Despite the federal prohibition on supply and possession — outside approved clinical research, the Food and Drug Administration's Expanded Access program, and some religious exemptions — some state and local governments are loosening their approaches to some psychedelics. In fact, some states are implementing or considering approaches that legalize some forms of supply to adults for any reason. It seems likely that more jurisdictions will consider and implement alternative policies to prohibiting the nonclinical supply of some psychedelics, possibly including retail sales. The primary goal of this mixed-methods report is to present new data and analysis to help inform policymakers participating in these discussions in the United States, but much of this report should also be useful to decisionmakers in other countries. These insights should also be useful to anyone who is interested in learning more about these substances and the public policy issues surrounding them.